Why Is Gadolinium Contrast Used in MRI for Kienböck Disease?
At a Glance
Gadolinium contrast may be added to an MRI for Kienböck disease to show clues about blood supply and whether parts of the lunate bone remain alive. These findings can support surgical planning but cannot alone predict healing or choose the right operation.
In this answer
5 sections
Summary: Contrast may give the radiologist extra information about the lunate bone’s vascularity (blood supply), but it cannot by itself tell whether the bone will heal or perfectly determine which operation you need.
If you are reading your MRI report for Kienböck disease, you may notice terms like “gadolinium contrast” or “enhancement.” Gadolinium is a specialized contrast agent (often called a dye) given through an IV during some MRI scans. It is used to help your doctors gather clues about which parts of your lunate (a small bone in the center of your wrist) might still be receiving a blood supply [1].
Because Kienböck disease is a condition involving impaired blood supply to the lunate, this contrast helps your surgeon estimate the extent of the bone’s vascularity [1][2]. However, not every Kienböck patient needs an MRI with contrast; it is used selectively when the surgical team needs additional information about tissue viability to plan your treatment.
What is Gadolinium Contrast?
An MRI (Magnetic Resonance Imaging) uses strong magnets and radio waves to create detailed pictures of the inside of your wrist. While a standard MRI is excellent for looking at the physical structure of your bones and joints, adding a gadolinium-based contrast agent changes the MRI signal to highlight differences in tissue vascularity [1][3]. A conventional contrast MRI does not directly measure or display the physical flow of blood. Instead, the contrast agent travels through your bloodstream and alters how the tissues look on the scan.
What Does “Enhancement” Mean?
When you read the word enhancement on an MRI report, it means the radiologist detected a relative MRI signal change in that specific tissue after the contrast was given.
- Enhancing areas: If a portion of your lunate bone enhances, it may suggest that the tissue there still has some blood supply, is still viable (alive), or is actively trying to heal [1][4].
- Non-enhancing areas: If an area does not enhance, it may suggest that the blood supply is reduced and the bone tissue is necrotic (dead) [1].
However, enhancement is not a perfect test. A lack of enhancement on the MRI does not definitively prove that the entire area is irreversibly dead, as technical factors or the timing of the scan can also affect the results [3][4]. Your radiologist and surgeon will interpret these clues together with the rest of your clinical picture.
How Contrast Helps Guide Your Treatment
The treatment for Kienböck disease is highly individualized. While the pattern of contrast enhancement provides one additional clue for surgical planning, it is not a stand-alone test that makes the decision for you [4]. Surgeons generally divide operations into two broad categories:
- Joint-Preserving Options: If your lunate has not collapsed and the MRI shows some enhancement, your surgeon might consider a joint-preserving procedure to try to improve vascularity [5][6]. This might involve a vascularized bone graft, where a surgeon moves a piece of bone with its own blood vessel into the lunate [6][7]. While this aims to support healing, enhancement alone does not guarantee that you are a candidate, nor does the surgery guarantee a perfect result [6][8].
- Salvage Options: If the disease is advanced, the term “salvage” is used by surgeons to describe pain-relieving operations [9]. If the lunate is severely damaged or mostly non-enhancing, preserving the original joint structure is less likely to be successful [5]. In these later stages, your surgeon may recommend a partial wrist fusion (arthrodesis) or removing certain carpal (wrist) bones to reduce pain and preserve as much function as possible [9][4].
Is Contrast the Only Factor?
No. To make the best recommendation, your surgeon will combine the contrast MRI findings with several other critical pieces of information [4]:
- Lichtman Stage: The formal stage of your disease, which looks at whether the lunate has collapsed or fragmented [10][2].
- Ulnar Variance: The relative lengths of your two forearm bones, which affects the pressure on your lunate.
- Cartilage Health: Whether the smooth cartilage that cushions the surrounding joints is preserved or shows signs of arthritis [4].
- Your Personal Context: Your symptoms, age, daily activities, and previous treatments.
Your care team looks at the entire picture—not just the enhancement—to choose the safest and most effective path forward for your wrist [4][3].
Before Your Scan: Gadolinium Safety
If a gadolinium-based contrast agent is recommended, you will receive it through an IV. Modern gadolinium agents are generally well-tolerated, but you should always inform the imaging team about:
- Kidney Issues: Severe kidney impairment can increase the risk of a rare condition called nephrogenic systemic fibrosis (NSF) [11]. However, the modern “Group II” agents used today have a very low reported risk of NSF, and a medically necessary MRI generally should not be delayed solely because of chronic kidney disease [12][13].
- Prior Reactions: Allergic-like reactions (such as hives, wheezing, or facial swelling) are uncommon, but a history of a previous reaction increases your risk [14].
- Pregnancy and Breastfeeding: Your clinical team should weigh the necessity of the contrast scan if you are pregnant, trying to conceive, or breastfeeding [15].
Common questions in this guide
Why might I receive gadolinium during an MRI for Kienböck disease?
What does enhancement or non-enhancement mean in the lunate?
Can a contrast MRI tell me which Kienböck operation I need?
What other findings affect treatment for Kienböck disease?
Is gadolinium contrast safe if I have kidney disease or might be pregnant?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on Kienbock disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What does the enhancement pattern on my MRI suggest about my lunate's vascularity or viability?
- 2.What is my formal Lichtman stage, and is there any evidence of lunate collapse or cartilage damage?
- 3.Based on my ulnar variance and the health of my wrist, am I a candidate for a joint-preserving surgery?
- 4.What are the specific goals and trade-offs of the procedure you are recommending for me?
- 5.If I don't have surgery now, how might the disease progress?
References
References (15)
- 1
The Signal-Compromised Lunate.
Grunz JP, Luetkens KS, Schmitt R
Seminars in musculoskeletal radiology 2025; (29(6)):863-870 doi:10.1055/s-0045-1810630.
PMID: 41338206 - 2
Precision Medicine for Kienböck Disease in the 21st Century.
Lichtman DM, Pientka WF, MacLean S, Bain G
The Journal of hand surgery 2022; (47(7)):677-684 doi:10.1016/j.jhsa.2022.03.014.
PMID: 35809999 - 3
Perfusion Imaging of the Musculoskeletal System.
Griffith JF, Yip SWY, van der Heijden RA, et al.
Magnetic resonance imaging clinics of North America 2024; (32(1)):181-206 doi:10.1016/j.mric.2023.07.004.
PMID: 38007280 - 4
Kienböck Disease: Moving Forward.
Lichtman DM, Pientka WF, Bain GI
The Journal of hand surgery 2016; (41(5)):630-8.
PMID: 27055625 - 5
A 40-Year Retrospective Evaluation of Vascularized Bone Grafting for Kienböck Disease.
Rames JD, Emanuels AF, Tunaboylu MF, Moran SL
The Journal of hand surgery 2026; (51(1)):13.e1-13.e9 doi:10.1016/j.jhsa.2025.07.025.
PMID: 40879579 - 6
Vascularized Bone Flaps for the Treatment of Kienböck Disease.
Florczynski MM, Chung KC
Hand clinics 2022; (38(4)):435-446 doi:10.1016/j.hcl.2022.03.007.
PMID: 36244711 - 7
Kienböck's disease: preventing disease progression in early-stage disease.
Salva-Coll G, Esplugas M, Carreño A, Lluch-Bergada A
The Journal of hand surgery, European volume 2023; (48(3)):246-256 doi:10.1177/17531934221146851.
PMID: 36799262 - 8
Is Joint Levelling Procedure Better than Temporary Scaphocapitate Pinning in Patients Undergoing Vascularized Bone Graft for Kienböck Disease?
Jung HS, Lee HW, Park MJ
The journal of hand surgery Asian-Pacific volume 2019; (24(4)):428-434 doi:10.1142/S2424835519500541.
PMID: 31690195 - 9
Influence of carpal-ulnar translation on clinical outcome after scaphocapitate arthrodesis for the treatment of late-stage Kienböck disease.
Park JH, Kang JW, Choi JS, et al.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2022; (75(1)):348-355 doi:10.1016/j.bjps.2021.08.031.
PMID: 34666943 - 10
Simplifying the Decision-Making Process in the Treatment of Kienböck's Disease.
Tee R, Butler S, Ek ET, Tham SK
Journal of wrist surgery 2024; (13(4)):294-301 doi:10.1055/s-0043-1778064.
PMID: 39027019 - 11
Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
McWilliams RG, Frabizzio JV, De Backer AI, et al.
Journal of magnetic resonance imaging : JMRI 2020; (51(2)):607-614 doi:10.1002/jmri.26851.
PMID: 31287213 - 12
Use of iodinated and gadolinium-based contrast media in patients with chronic kidney disease: Consensus statements from nephrologists, cardiologists, and radiologists at National Taiwan University Hospital.
Wang KC, Lin LC, Pan SY, et al.
Journal of the Formosan Medical Association = Taiwan yi zhi 2026; (125(3)):261-267 doi:10.1016/j.jfma.2025.01.019.
PMID: 39870554 - 13
Nephrogenic Systemic Fibrosis in Patients with Advanced Renal Dysfunction Following Gadolinium-based Contrast Agents.
Mallepally A, Kidd JM, Grizzard JD, et al.
Radiology 2025; (317(3)):e251794 doi:10.1148/radiol.251794.
PMID: 41400469 - 14
Allergic-like Hypersensitivity Reactions to Gadolinium-based Contrast Agents: An 8-year Cohort Study of 154 539 Patients.
Ahn YH, Kang DY, Park SB, et al.
Radiology 2022; (303(2)):329-336 doi:10.1148/radiol.210545.
PMID: 35191737 - 15
Incidence and Risk Factors for Gadolinium-Based Contrast Agent Immediate Reactions.
Costello JR, Kalb B, Martin DR
Topics in magnetic resonance imaging : TMRI 2016; (25(6)):257-263 doi:10.1097/RMR.0000000000000109.
PMID: 27748714
This page is for informational purposes only and does not constitute medical advice. A radiologist and hand surgeon should interpret your MRI and discuss whether gadolinium is appropriate and what the findings mean for your treatment.